Search Medical Condition
Please enter condition
Please choose location

East Melbourne, Australia Clinical Trials

A listing of East Melbourne, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (361) clinical trials

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

This is a multicenter, open-label, single-arm study of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL). The study will consist of an initial lead-in phase (in which a dose of E7777 will be selected), followed by the Main Study. Participants will move through three phases while on ...

Phase

0.0 miles

Learn More »

Study of the Safety Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors

This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-A317 in patients with advanced tumors.

Phase

0.0 miles

Learn More »

A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel for Neuroendocrine Tumours

The objective of the PRELUDE study is to describe the use of lanreotide Autogel® (LAN ATG) combined with Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of progressive neuroendocrine tumours located in the lung or in the digestive system as there is currently limited data on these treatments used together ...

Phase N/A

0.0 miles

Learn More »

Phase

0.0 miles

Learn More »

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

This is a randomized (treatment assigned by chance), double-blind (neither patient nor investigator know which treatment is given), multicenter study to evaluate the safety and efficacy of siltuximab compared with placebo in patients with high-risk SMM. Approximately 100 patients will receive either siltuximab or placebo by intravenous (IV, injection into ...

Phase

0.0 miles

Learn More »

MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

This study will determine whether there is a difference in local recurrence rates and melanoma survival rates for patients treated with either a 1cm excision margin or 2cm margin for both intermediate & high risk melanomas. The study is designed to be able to prove or disprove that there is ...

Phase

0.33 miles

Learn More »

A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma

The primary purpose of this study is to determine whether ASN-002 alone or in combination with 5-FU is safe and effective in the treatment of nodular basal cell carcinoma (nBCC). Patients aged 18 or over, who have been diagnosed with nodular Basal Cell Carcinoma (nBCC), may be eligible to join ...

Phase

0.33 miles

Learn More »

Trial of Switching Between Intravitreal Bevacizumab (Avastin )& Intravitreal Dexamethasone (Ozurdex ) for Persistent Diabetic Macular Oedema

A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab (Avastin®) and Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema (SwitchDMO)

Phase

0.33 miles

Learn More »

A Dose Escalation Study to Investigate the Safety Pharmacokinetics (PK) Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed Refractory Hematologic Malignancies

This is an open-label repeat dose, multicenter, 2-part study to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for GSK525762 given once-daily (QD) orally. Part 1 of the study is a dose escalation phase to select the recommended Part 2 dose (RP2D) based on the ...

Phase

0.33 miles

Learn More »

Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma

OBJECTIVES: Primary - To determine the overall survival in patients with untreated mantle cell lymphoma treated with fludarabine phosphate and cyclophosphamide with vs without rituximab. Secondary - To determine the progression-free survival in patients treated with this regimen. - To determine the toxicity of this regimen in these patients. - ...

Phase

0.33 miles

Learn More »